CohBar Nominates CB5138 Analog as Lead Clinical Candidate for Idiopathic Pulmonary Fibrosis and other Fibrotic Diseases

CohBar Nominates CB5138 Analog as Lead Clinical Candidate for Idiopathic Pulmonary Fibrosis and other Fibrotic Diseases
MENLO PARK, Calif., March 16, 2021 (GLOBE NEWSWIRE) — CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced the selection of CB5138-3 as its lead candidate for advancement into IND-enabling activities. CB5138-3 is a CB5138 Analog, a novel class of molecules derived from a natural, mitochondrially encoded peptide source discovered by CohBar, with potential for treatment of Idiopathic Pulmonary Fibrosis (IPF) and other fibrotic diseases. IPF is a chronic, progressive, debilitating and usually fatal interstitial lung disease that affects approximately 100,000 people in the U.S. This orphan disease results in fibrotic scarring of the lungs.

Related Keywords

Canada , Canadian , Nancy Thompson , Jordyn Tarazi , Steven Engle , Exchange Commission , Cohbar Inc , Nasdaq , Vorticom Inc , Idiopathic Pulmonary Fibrosis , Chief Executive , American Thoracic Society Virtual Annual Meeting , Ashcroft Score , Pulmonary Fibrosis , Private Securities Litigation Reform Act , கனடா , கனடியன் , நான்சி தாம்சன் , பரிமாற்றம் தரகு , நாஸ்டாக் , தலைமை நிர்வாகி , அமெரிக்கன் தொராசி சமூகம் மெய்நிகர் ஆண்டு சந்தித்தல் , ஆஷ்கிராஃப்ட் மதிப்பெண் , நுரையீரல் ஃபைப்ரோஸிஸ் , ப்ரைவேட் பத்திரங்கள் வழக்கு சீர்திருத்தம் நாடகம் ,